Skip to content
Research Article Open access CC BY 4.0

A New Genetic Insight for Orphan Renal Disorder, Fabry: A Review

Pragati Karemore, Dinesh Kumar, Anil Kumar

Journal of Pharmaceutical Research International · pp. 563–576 · Published 15 Dec 2021

10.9734/jpri/2021/v33i58A34152

Abstract

Fabry is the rare X-linked genetic disorder caused due to mutation in Alpha –Galactosidase encoding GLA gene mutation in chromosome number 22. It has wide diversification in prevalence due to clinical heterozygosity. There are some potential biomarkers for the evaluation of normal or altered genes responsible for Fabry. Advances in the research of biomarkers over the years have made significant development for several clinical indicators, viz.  urine-derived cells, oxidative stress, DNA methylation, etc. At present days the recommended therapies for the disease are Enzyme Replacement Therapy (ERT), Chaperone therapy (CT), and mRNA-based therapy, besides, some second-generation therapies which are still under clinical trials.

Rare inherited disease genomic variants fabry biomarker diagnostics treatment

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

20

Page views

0

PDF downloads

7

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.